KB-1241

RG7716-ANG2-hIgG1

Home » Antibody » RG7716-ANG2-hIgG1

Background

RG7716 (also known as Faricimab) was an investigational drug developed by Genentech, a subsidiary of Roche. RG7716 is a novel bispecific antibody designed to target two key proteins involved in various eye diseases, particularly retinal diseases like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). RG7716-ANG2-hIgG1 is is a monoclonal antibody specifically designed to target ANG2 in order to provide targeted therapy.

Specifications

Catalog Number:
KB-1241
Cell Line Name:
RG7716-ANG2-hIgG1
Price:
0
Host Cell Line:
EXPI-CHO
Target:
ANG2
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Anti-VEGF/anti-angiopoietin-2 bispecific antibody RG7716 in diabetic macular edema: complete 36-week results from the phase 2, multicenter, randomized, active treatment-controlled BOULEVARD clinical trial
Please enable JavaScript in your browser to complete this form.